Cosmetic composition of liquid crystal lipid particles for personal care applications

Abstract

To provide: a topical composition which effectively improve the skin barrier function by enhancing the skin's own ability to maintain and / or repair the strength of its barrier, so that the protective barrier formed is completely natural; and a skin composition which exhibits enhanced skin protection properties and enhanced skin moisturization.SOLUTION: The presently claimed invention relates to liquid crystal lipid particles. The presently claimed invention relates to liquid crystal lipid particles which are used in a topical composition which has high moisturization efficacy, excellent skin feel, skin softness and skin smoothness benefits. The liquid crystal lipid particles are effective in improving the barrier function and protecting the skin from harmful pollutants, and also enhance the skin moisturizing effect.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to liquid crystalline lipid particles. In particular, the present invention relates to liquid crystalline lipid particles for use in topical compositions. Topical compositions containing liquid crystalline lipid compositions have the advantages of high moisturizing efficacy, excellent skin feel, skin softness, and skin smoothness. [Background technology]

[0002] Skin plays a very important role as a barrier membrane that prevents any loss of biologically essential components, such as water, while at the same time helping to protect against any biological, chemical or physical insults, such as external microorganisms, chemicals, ultraviolet rays, etc. The part that functions as a barrier membrane is the stratum corneum, or horny layer, which is about 20 μm thick and is located in the outermost layer of the skin, forming a tough barrier membrane in the structure of keratinocytes stacked as bricks that bind together via intercellular lipids that act as mortar.

[0003] The stratum corneum serves an important barrier function, the most important of which is to prevent excessive transepidermal water loss ("TEWL"). In addition to slowing TEWL, the sheets of lipid lamellar membrane also provide protection against the invasion of foreign chemicals and microorganisms.

[0004] Emulsifiers that form lamellar liquid crystals are sold by cosmetic ingredient suppliers as mimicking the multi-lamellar lipid structure of the stratum corneum.

[0005] In the field of cosmetics, it is believed that smaller particles are easily absorbed by the skin and repair damages easily and more efficiently. The introduction of nanotechnology in functional cosmetics aims to make perfumes last longer, sunscreens protect the skin, anti-aging creams fight age, and moisturizers maintain skin hydration. Some of the innovations based on nanotechnology are nanoemulsions (transparent and have unique touch and texture properties), nanocapsules (used in skin care products), nanopigments (transparent and increase the efficiency of sunscreen products), liposomal formulations (containing vesicles of conventional cosmetic materials that protect oxygen- or light-sensitive cosmetic ingredients), niosomes, nanocrystals, solid lipid nanoparticles, carbon nanotubes, fullerenes, and dendrimers. The major advantages of using nanoparticles in functional cosmetics include improved stability of cosmetic ingredients (e.g., vitamins, unsaturated fatty acids and antioxidants) by encapsulation within the nanoparticles; efficient protection of the skin from harmful ultraviolet (UV) rays; aesthetically pleasing products (e.g., the use of smaller particles of active minerals in mineral sunscreens allows them to be applied without leaving a noticeable white appearance); targeting of active ingredients to desired sites and controlled release of active ingredients for long-term efficacy.

[0006] WO 2005 / 108383 A1 discloses an oil-in-water emulsion comprising a mixture of at least two sucrose esters in combination with at least one solid fatty alcohol, the mixture forming a multi-lamellar liquid crystal network that effectively moisturizes and protects the skin and provides a useful vehicle for the delivery of active ingredients.

[0007] US 2009 / 0239956 A1 relates to lamellar liquid crystal compositions for cosmetic use, which contain one or more polyglycerol monoethers each having a specific structure and are used to remove make-up and cosmetic containing cosmetic compositions.

[0008] US 2012 / 0282357 A1 discloses a method for regulating the amount of calcium ions in the epidermis, comprising applying to the skin of a subject a material for improving skin barrier function, the material being selected from the group consisting of Pimpinella extract, Asteroidea extract, L-carnitine, royal jelly hydrolysate, α,ε-bis(γ-N-lauroylglutamyl)lysine, Palmaria extract, ε,γ-glutamyl lysine, Coptis japonica extract and citrus aurantium peel extract.

[0009] WO 2016 / 003118 A1 describes a cholesterol-lowering agent that improves the feeling of use. Rick The present invention relates to a multi-phase cosmetic composition comprising liquid crystals.

[0010] Efforts have been made to improve the skin barrier function by using several methods such as natural extracts formulated into skin creams, lotions, etc., while these extracts are efficient in biologically improving the skin barrier function, they do not improve the physical barrier function. Summary of the Invention [Problem to be solved by the invention]

[0011] Therefore, there remains a need to effectively improve skin barrier function by improving the skin's own ability to maintain and / or repair the strength of its barrier, such that the protective barrier formed is completely natural. Furthermore, there is also a need to have skin compositions that exhibit improved skin protective properties and improved skin moisturization. [Means for solving the problem]

[0012] Surprisingly, it has been found that the liquid crystalline lipid particles of the present invention are effective in improving the barrier function and protecting the skin from harmful pollutants, and also enhance skin moisturizing effect.

[0013] Liquid crystalline lipid particles are another type of system that offers the dual benefits of liquid and solid phases. These particles are easy to manufacture and can offer a number of advantages.

[0014] Thus, in one aspect, the present invention relates to a method for reducing dust adhesion to skin comprising applying to the skin at least one liquid crystalline lipid particle, the liquid crystalline lipid particle comprising: At least one compound of formula (I)

[0015] [ka] [In the formula, m is an integer ranging from 10 to 24, and n is an integer ranging from 1 to 25] At least one compound of formula (II)

[0016] [ka] [wherein a is an integer ranging from 10 to 24], At least one compound of formula (III)

[0017] [ka] [wherein x is an integer ranging from 10 to 24, and y is an integer ranging from 10 to 25], At least one compound of formula (IV)

[0018] [ka] [wherein p is an integer ranging from 10 to 16], At least one compound of formula (V)

[0019] [ka] [In the formula, A and B each independently represent a hydrogen atom or an alkaline earth metal; R is a linear or branched, saturated or unsaturated C 10 ~C 20 an aliphatic group], and At least one compound of formula (VI)

[0020] [ka] [In the formula, r is an integer ranging from 9 to 18, and M is a hydrogen atom, an alkaline earth metal, or an alkaline earth metal.] The present invention includes compounds represented by the general formulas (I) to (VI).

[0021] In yet another aspect, the present invention relates to the use of at least one liquid crystalline lipid particle for reducing dust adhesion to skin, comprising: The liquid crystalline lipid particles are At least one compound of formula (I)

[0022] [ka] [In the formula, m is an integer ranging from 10 to 24, and n is an integer ranging from 1 to 25] At least one compound of formula (II)

[0023] [ka] [wherein a is an integer ranging from 10 to 24], At least one compound of formula (III)

[0024] [ka] [wherein x is an integer ranging from 10 to 24, and y is an integer ranging from 10 to 25], At least one compound of formula (IV)

[0025] [ka] [wherein p is an integer ranging from 10 to 16], At least one compound of formula (V)

[0026] [ka] [In the formula, A and B each independently represent a hydrogen atom or an alkaline earth metal; R is a linear or branched, saturated or unsaturated C 10 ~C 20 aliphatic groups], and At least one compound of formula (VI)

[0027] [ka] [In the formula, r is an integer ranging from 9 to 18, and M is a hydrogen atom, an alkaline earth metal, or an alkaline earth metal.] The present invention includes compounds represented by the general formulas (I) to (VI).

[0028] Another aspect of the present invention relates to a topical composition comprising at least one liquid crystal particle as described hereinabove and below, at least one thickening agent, and water. [Brief description of the drawings]

[0029] [Figure 1] FIG. 1 illustrates orthorhombic lateral packing of liquid crystalline lipid particles. [Diagram 2] FIG. 1 shows transparent / flexible lipid membranes formed by treatment of liquid crystalline lipid particles. [Diagram 3] FIG. 1 shows that the membrane formed by liquid crystalline lipid particles has a liquid repellent effect. [Figure 4] FIG. 1 shows that films formed by liquid crystalline lipid particles have an anti-adhesion effect. [Diagram 5] FIG. 1 shows the increased moisturizing effect of a composition containing liquid crystalline lipid particles as measured by a Corneometer. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] Before describing the present compositions and formulations of the present invention, it is to be understood that the present invention is not limited to the particular compositions and formulations described, as such may, of course, vary. It is also to be understood that the terms used herein are not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0031] Hereinafter, when a group is defined as including at least a certain number of embodiments, this is also intended to encompass a group consisting of preferably only those embodiments. Moreover, the terms "first," "second," "third," or "a," "b," "c," etc. in the present description and claims are used to distinguish between similar elements and are not necessarily used to describe a sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances, and that the embodiments of the present invention described herein can be operated in other sequences than those described or illustrated herein. Where the terms "first", "second", "third" or "(A)", "(B)" and "(C)" or "(a)", "(b)", "(c)", "(d)", "i", "ii" etc. refer to steps of a method or use or assay, unless otherwise indicated in the application as expressly stated herein above or below, the times or time intervals between the steps are not consistent, i.e. the steps may be performed simultaneously or there may be a time interval of seconds, minutes, hours, days, weeks, months or even years between such steps.

[0032] Furthermore, ranges defined throughout this specification are inclusive of the end values, i.e., a range of 1 to 10 implies that both 1 and 10 are included within its range. For the avoidance of doubt, Applicant reserves the right to any equivalents under applicable law.

[0033] In the following passages, different aspects of the present invention are defined in more detail. Each aspect so defined may be combined with any other aspect or aspects, unless expressly indicated otherwise. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.

[0034] Throughout this specification, the reference to "one embodiment" or "an embodiment" means that a particular feature, structure, or attribute described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the phrase "in one embodiment" or "in an embodiment" in various places throughout this specification may, but do not necessarily, all refer to the same embodiment. Furthermore, particular features, structures, or attributes may be combined in any suitable manner in one or more embodiments, as would be apparent to one of ordinary skill in the art from this disclosure. Furthermore, while some embodiments described herein include some features but not other features included in other embodiments, combinations of features of different embodiments are intended to be within the scope of the present invention and form different embodiments, as would be understood by one of ordinary skill in the art. For example, in the appended claims, any of the claimed embodiments may be used in any combination.

[0035] By "topical application" is meant applying or spreading the composition directly onto the skin surface of the human or animal body, preferably onto the face, scalp, feet, limbs or trunk.

[0036] The present invention relates to a method for reducing dust adhesion to skin, comprising applying at least one liquid crystalline lipid particle to the skin, The liquid crystalline lipid particles are At least one compound of formula (I)

[0037] [ka] [In the formula, m is an integer ranging from 10 to 24, and n is an integer ranging from 1 to 25] At least one compound of formula (II)

[0038] [ka] [wherein a is an integer ranging from 10 to 24], At least one compound of formula (III)

[0039] [ka] [wherein x is an integer ranging from 10 to 24, and y is an integer ranging from 10 to 25], At least one compound of formula (IV)

[0040] [ka] [wherein p is an integer ranging from 10 to 16], At least one compound of formula (V)

[0041] [ka] [In the formula, A and B each independently represent a hydrogen atom or an alkaline earth metal; R is a linear or branched, saturated or unsaturated C 10 ~C 20 an aliphatic group], and At least one compound of formula (VI)

[0042] [ka] [In the formula, r is an integer ranging from 9 to 18, and M is a hydrogen atom, an alkaline earth metal, or an alkaline earth metal.] The present invention includes compounds represented by the general formulas (I) to (VI).

[0043] In one embodiment, the present invention relates to the use of at least one liquid crystalline lipid particle for reducing dust adhesion to the skin, The liquid crystalline lipid particles are At least one compound of formula (I)

[0044] [ka] [In the formula, m is an integer ranging from 10 to 24, and n is an integer ranging from 1 to 25] At least one compound of formula (II)

[0045] [ka] [wherein a is an integer ranging from 10 to 24], At least one compound of formula (III)

[0046] [ka] [wherein x is an integer ranging from 10 to 24, and y is an integer ranging from 10 to 25], At least one compound of formula (IV)

[0047] [ka] [wherein p is an integer ranging from 10 to 16], At least one compound of formula (V)

[0048] [ka] [In the formula, A and B each independently represent a hydrogen atom or an alkaline earth metal; R is a linear or branched, saturated or unsaturated C 10 ~C 20 an aliphatic group], and At least one compound of formula (VI)

[0049] [ka] [In the formula, r is an integer ranging from 9 to 18, and M is a hydrogen atom, an alkaline earth metal, or an alkaline earth metal.] The present invention includes compounds represented by the general formulas (I) to (VI).

[0050] In one embodiment of the present invention, the topical composition comprises at least one liquid crystal particle as defined above, at least one thickener, and water.

[0051] The liquid crystalline lipid particles of the present invention are represented by the compounds of the general formulas (I) to (IV).

[0052] [ka] [In the formula, m is an integer ranging from 10 to 24, and n is an integer ranging from 1 to 25]

[0053] [ka] [wherein a is an integer ranging from 10 to 24],

[0054] [ka] [wherein x is an integer ranging from 10 to 24, and y is an integer ranging from 10 to 25], and

[0055] [ka] [In the formula, p is an integer ranging from 10 to 16] The compound includes at least one compound selected from the group consisting of:

[0056] The liquid crystal particles of the present invention comprise at least one compound selected from the group consisting of compounds represented by general formulas (I) to (IV) and at least one compound represented by general formula (V) or (VI):

[0057] [ka] [In the formula, A and B each independently represent a hydrogen atom or an alkaline earth metal; R is a linear or branched, saturated or unsaturated C 10 ~C 20 an aliphatic group],

[0058] [ka] [In the formula, r is an integer ranging from 9 to 18, and M is a hydrogen atom, an alkaline earth metal, or an alkaline earth metal.] Includes:

[0059] In one embodiment of the present invention, the liquid crystalline lipid particles comprise at least one compound represented by general formula (I) and at least one compound selected from the group consisting of compounds represented by general formulas (II), (III) and (IV).

[0060] In one embodiment of the present invention, the liquid crystalline lipid particles comprise at least one compound represented by general formula (I) and at least one compound selected from the group consisting of compounds represented by general formulas (II), (III), (IV), (V) and (VI).

[0061] In yet another embodiment of the present invention, the liquid crystalline lipid particles comprise at least one compound represented by general formula (II) and at least one compound selected from the group consisting of compounds represented by general formulas (I), (III) and (IV).

[0062] In yet another embodiment of the present invention, the liquid crystalline lipid particles comprise at least one compound represented by general formula (II) and at least one compound selected from the group consisting of compounds represented by general formulas (I), (III), (IV), (V) and (VI).

[0063] In yet another embodiment of the present invention, the liquid crystalline lipid particles comprise at least one compound represented by general formula (III) and at least one compound selected from the group consisting of compounds represented by general formulas (I), (II) and (IV).

[0064] In yet another embodiment of the present invention, the liquid crystalline lipid particles comprise at least one compound represented by general formula (III) and at least one compound selected from the group consisting of compounds represented by general formulas (I), (II), (IV), (V) and (VI).

[0065] In yet another embodiment of the present invention, the liquid crystalline lipid particles comprise at least one compound represented by general formula (IV) and at least one compound selected from the group consisting of compounds represented by general formulas (I), (II), (III), (V) and (VI).

[0066] In a further embodiment of the present invention, the liquid crystal lipid particles comprise at least one compound represented by general formula (I) and at least one compound represented by general formula (II) and at least one compound represented by general formula (III) and at least one compound represented by general formula (IV).

[0067] In another embodiment of the present invention, the liquid crystal lipid particles comprise at least one compound represented by general formula (I), at least one compound represented by general formula (II), at least one compound represented by general formula (III), at least one compound represented by general formula (IV), and at least one compound represented by general formula (V).

[0068] In a further embodiment of the present invention, the liquid crystal lipid particles comprise at least one compound represented by general formula (I) and at least one compound represented by general formula (II) and at least one compound represented by general formula (III) and at least one compound represented by general formula (IV) and at least one compound represented by general formula (VI).

[0069] In a further embodiment of the present invention, the liquid crystal lipid particles comprise at least one compound represented by general formula (I) and at least one compound represented by general formula (II) and at least one compound represented by general formula (III) and at least one compound represented by general formula (IV) and at least one compound represented by general formula (VI) and at least one compound represented by general formula (V) and at least one compound represented by general formula (VI).

[0070] In one embodiment of the present invention, the liquid crystalline lipid particles are provided by at least one compound represented by the general formula (I):

[0071] [ka] [In the formula, m is an integer ranging from 10 to 24, and n is an integer ranging from 1 to 25.] Includes.

[0072] In one embodiment of the present invention, the at least one compound of general formula (I) is selected from the group consisting of ceteareth, polyoxyethylene stearyl ether and polyoxyethylene cetyl ether.

[0073] In one embodiment of the present invention, the at least one compound of general formula (I) is selected from the group consisting of ceteareth-12, ceteareth-12, ceteareth-30.

[0074] In the most preferred embodiment of the present invention, the at least one compound of general formula (I) is selected from the group consisting of ceteareth-12, ceteareth-12.

[0075] In one embodiment of the present invention, at least one compound of general formula (II)

[0076] [ka] In the formula, a is an integer ranging from 10 to 24.

[0077] In one embodiment of the present invention, the at least one compound of general formula (II) is selected from the group consisting of glycerol stearate, glycerol laurate and glycerol palmitate, glycerol caprylate, glycerol myristate.

[0078] In a preferred embodiment of the present invention, the at least one compound of general formula (II) is glyceryl stearate.

[0079] In one embodiment of the present invention, at least one compound of general formula (III)

[0080] [ka] In the formula, x is an integer in the range of 10 to 24, inclusive, and y is an integer in the range of 10 to 25, inclusive.

[0081] In one embodiment of the present invention, the at least one compound of general formula (III) is selected from the group consisting of myristyl myristate, myristyl palmitate, myristyl stearate, myristyl isostearate, myristyl oleate, myristyl behenate, myristyl erucate, cetyl myristate, cetyl palmitate, cetyl stearate, cetyl isostearate, cetyl oleate, cetyl behenate, cetyl erucate, stearyl myristate, stearyl palmitate, stearyl stearate, stearyl isostearate, stearyl oleate, stearyl behenate, stearyl erucate, isostearyl myristate, isostearyl palmitate, stearic acid ... isostearyl isoate, isostearyl isostearate, isostearyl oleate, isostearyl behenate, isostearyl oleate, oleyl myristate, oleyl palmitate, oleyl stearate, oleyl isostearate, oleyl oleate, oleyl behenate, oleyl erucate, behenyl myristate, behenyl palmitate, behenyl stearate, behenyl isostearate, behenyl oleate, behenyl behenate, behenyl erucate, erucyl myristate, erucyl palmitate, erucyl stearate, erucyl isostearate, erucyl oleate, erucyl behenate, and erucyl erucate.

[0082] In a further embodiment of the present invention, the at least one compound of general formula (III) is selected from the group consisting of cetyl palmitate, myristyl myristate, tetradecyl tetradecanoate and behenyl behenate.

[0083] In a preferred embodiment of the present invention, the at least one compound of general formula (III) is selected from the group consisting of cetyl palmitate, myristyl myristate.

[0084] In one embodiment of the present invention, at least one compound of general formula (IV)

[0085] [ka] In the formula, p is an integer ranging from 10 to 16.

[0086] In yet another embodiment of the present invention, the at least one compound of general formula (IV) is selected from the group consisting of lauryl alcohol, tridecyl alcohol, myristyl alcohol, pentadecyl alcohol, cetyl alcohol, palmitoleic alcohol, heptadecyl alcohol and stearyl alcohol or mixtures thereof.

[0087] In a preferred embodiment of the present invention, the at least one compound of general formula (IV) is selected from the group consisting of lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol or mixtures thereof.

[0088] In the most preferred embodiment of the present invention, the at least one compound of general formula (IV) is a mixture of cetyl alcohol and stearyl alcohol.

[0089] In one embodiment of the present invention, at least one compound of general formula (V)

[0090] [ka] In the formula, A and B are each independently a hydrogen atom or an alkaline earth metal, and R is a linear or branched, saturated or unsaturated C 10 ~C 20 It is an aliphatic group.

[0091] In one embodiment of the present invention, in at least one compound of general formula (V), A and B are each independently an alkaline earth metal, R is a linear or branched, saturated or unsaturated C 10 ~C 20 It is an aliphatic group.

[0092] In a further embodiment of the present invention, in at least one compound of general formula (V), R is n-decyl, iso-decyl, n-undecyl, iso-undecyl, n-dodecyl, iso-dodecyl, n-tridecyl, iso-tridecyl, n-tetradecyl, iso-tetradecyl, n-pentadecyl, iso-pentadecyl, n-hexadecyl, iso-hexadecyl, n-heptadecyl, iso-heptadecyl, n-octadecyl, iso-octadecyl and n-octadecenyl.

[0093] In a further embodiment of the present invention, at least one compound of general formula (V) is disodium C 10 ~C 18 It is an alkyl sulfosuccinate.

[0094] In a preferred embodiment of the present invention, at least one compound of general formula (V) is disodium C 12 ~C 18 It is an alkyl sulfosuccinate.

[0095] In the most preferred embodiment of the present invention, at least one compound of general formula (V) is 16 ~C 18 It is an alkyl sulfosuccinate.

[0096] In one embodiment of the present invention, at least one compound of general formula (VI)

[0097] [ka] In the formula, r is an integer ranging from 9 to 18, and M is a hydrogen atom, an alkaline earth metal, or an alkaline earth metal.

[0098] In one embodiment of the present invention, in at least one compound of general formula (VI), M is sodium or potassium, and r is an integer ranging from 9 to 18.

[0099] In one embodiment of the present invention, the at least one compound of general formula (VI) is selected from the group consisting of sodium stearoyl glutamate, sodium lauroyl glutamate, sodium cocoyl glutamate, sodium myristoyl glutamate, potassium cocoyl glutamate, potassium lauroyl glutamate, and combinations thereof.

[0100] In one embodiment of the present invention, the at least one compound of general formula (VI) is selected from the group consisting of sodium lauroyl glutamate, sodium cocoyl glutamate, sodium myristoyl glutamate and sodium stearoyl glutamate.

[0101] In one embodiment of the present invention, the liquid crystalline lipid particles include ceteareth, glyceryl stearate, cetyl palmitate, cetyl alcohol and stearyl alcohol.

[0102] In yet another embodiment of the present invention, the liquid crystalline lipid particles comprise ceteareth, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol and stearyl alcohol.

[0103] In a further embodiment of the present invention, the liquid crystalline lipid particles are comprised of ceteareth, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol, and disodium C 10 ~C 18 The compound includes a compound selected from the group consisting of alkyl sulfosuccinates and sodium stearoyl glutamate.

[0104] In a preferred embodiment of the present invention, the liquid crystalline lipid particles are made of ceteareth-12, ceteareth-12, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol, and disodium C 16 ~C 18 The compound includes a compound selected from the group consisting of alkyl sulfosuccinates and sodium lauroyl glutamate.

[0105] In another preferred embodiment of the present invention, the liquid crystalline lipid particles are made of ceteareth-12, ceteareth-12, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol, and disodium C 12 ~C 14 The compound includes a compound selected from the group consisting of alkyl sulfosuccinates and sodium lauroyl glutamate.

[0106] In yet another preferred embodiment of the present invention, the liquid crystalline lipid particles are comprised of ceteareth-12, ceteareth-12, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol, and disodium C 12 ~C 14 The compound includes a compound selected from the group consisting of alkyl sulfosuccinates and sodium stearoyl glutamate.

[0107] In the most preferred embodiment of the present invention, the liquid crystalline lipid particles are comprised of ceteareth-12, ceteareth-12, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol, and disodium C 16 ~C 18 The compound includes a compound selected from the group consisting of alkyl sulfosuccinates and sodium stearoyl glutamate.

[0108] In one embodiment of the present invention, the liquid crystalline lipid particles have an average particle size of 20 nm to 500 nm as determined using dynamic light scattering using a Malvern DLS ZS90.

[0109] In one embodiment of the present invention, the liquid crystalline lipid particles have an average particle size of 20 nm to 300 nm, as determined using dynamic light scattering using a Malvern DLS ZS90.

[0110] In one embodiment of the present invention, the liquid crystalline lipid particles have an average particle size of 20 nm to 150 nm, as determined using dynamic light scattering using a Malvern DLS ZS90.

[0111] In one embodiment of the present invention the liquid crystalline lipid particles have an average particle size of 20nm, 30nm, 40nm, 50nm, 60nm, 70nm, 80nm, 90nm, 100nm, 110nm, 120nm, 130nm, 140nm or 150nm as determined using dynamic light scattering using a Malvern DLS ZS90.

[0112] The zeta potential of liquid crystalline lipid particles is a measure of the charge on the surface of the particle and is a measure of the stability of the lipid particle: the higher the zeta potential, the greater the stability.

[0113] In one embodiment of the present invention, the liquid crystalline lipid particles have a zeta potential of greater than 20 mV when measured at 40°C.

[0114] In one embodiment of the present invention, the liquid crystalline lipid particles have a zeta potential of greater than 30 mV when measured at 40°C.

[0115] In one embodiment of the present invention, the liquid crystalline lipid particles are prepared by using the phase inversion temperature method.

[0116] In a further embodiment of the present invention, the liquid crystalline lipid particles are prepared using the phase inversion temperature method disclosed in D. J. Mitchell et al., Phase behavior of polyoxyethylene surfactants with water. Mesophase structures and partial miscibility (cloud points), J. Chem. Soc. Farayday Trans., 79, 975-1000 (1983), which is incorporated herein by reference.

[0117] In one embodiment of the present invention, the liquid crystalline lipid particles have orthorhombic lateral packing.

[0118] In one embodiment of the present invention, the liquid crystalline lipid particles are included in a topical composition for application to the skin.

[0119] In one embodiment of the present invention, the liquid crystalline lipid particles form the base in any topical composition for application to the skin.

[0120] In one embodiment of the present invention, the at least one liquid crystalline lipid particle is present in an amount ranging from 1% to 30% by weight based on the total weight of the topical composition.

[0121] In a further embodiment of the present invention, the at least one liquid crystalline lipid particle is present in an amount ranging from 1% to 25% by weight, based on the total weight of the topical composition.

[0122] In a preferred embodiment of the present invention, the at least one liquid crystalline lipid particle is present in an amount ranging from 1% to 20% by weight based on the total weight of the topical composition.

[0123] In a most preferred embodiment of the present invention, the at least one liquid crystalline lipid particle is present in an amount ranging from 1% to 15% by weight, based on the total weight of the topical composition.

[0124] In one embodiment of the present invention, the topical composition is in the form of a cream, foam, lotion, gel, paste, spray, patch, spray patch, mousse or ointment.

[0125] In one embodiment of the present invention, the topical composition further comprises at least one adjuvant selected from the group consisting of anti-wrinkle actives, anti-acne actives, emulsifiers, antioxidants, emollients, self-tanning actives, skin lightening agents, sunscreens, UV absorbers, thickening agents, humectants, abrasives, absorbents, fragrances, buffers, opacifiers, colorants, preservatives, fillers, pH adjusters, and solvents.

[0126] In one embodiment of the present invention, the active agent is selected from the group consisting of retinol, hyaluronic acid, ceramides, niacinamide, vitamin E, anti-wrinkle agents such as alpha hydroxy acids, clindamycin, benzamycin, benzoyl peroxide, and anti-acne agents such as isotretinoin.

[0127] In one embodiment of the present invention, the skin lightening agent is selected from the group consisting of tretinoin, hydroquinone, resorcinol, arbutin, kojic acid, azelaic acid, vitamin C, glutathione, and alpha hydroxy acids.

[0128] In one embodiment of the present invention, the UV absorber or sunscreen may be, for example: p-aminobenzoic acid, its salts and derivatives (ethyl, isobutyl, glyceryl esters; p-dimethylaminobenzoic acid, diethylaminohydroxybenzoylhexyl benzoate); anthranilic acid esters (i.e., o-aminobenzoic acid esters; methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, terpinyl and cyclohexenyl esters); salicylic acid esters (amyl, phenyl, benzyl, menthyl, glyceryl and dipropylene glycol esters); ol esters;cinnamic acid derivatives (menthyl and benzyl esters, butyl cinnamoylpyruvate);dihydroxycinnamic acid derivatives (umbelliferone, methylumbelliferone, methylaceto-umbelliferone);trihydroxy-cinnamic acid derivatives (esculetin, methylesculetin, daphnetin and glucoside, esculin and daphnin);hydrocarbons (diphenylbutadiene, stilbene);dibenzalacetone and benzalacetophenone;naphtholsulfonates (sodium salt of 2-naphthol-3,6-disulfonic acid and 2-naphthol-3,6-disulfonic acid, -Naphthol-6,8-disulfonic acid sodium salts;Dihydroxy-naphthoic acid and its salts;o- and p-hydroxybiphenyl disulfonates;Coumarin derivatives (7-hydroxy, 7-methyl, 3-phenyl);Diazoles (2-acetyl-3-bromoindazole, phenylbenzoxazole, methylnaphthoxazole, various arylbenzothiazoles);Quinine salts (hydrogensulfate, sulfate, chloride, oleate and tannate);Hydroxy or methoxy substituted benzophenones;Uric acid and pyrouric acid;Tannic acid and its derivatives (butylcarbitol)(6-propylpiperonyl)ether; benzophenones (oxybenzene, sulisobenzone, dioxybenzone, benzoresorcinol, 2,2',4,4'-tetrahydroxybenzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, octabenzone; 4-isopropyldibenzoylmethane; butyl methoxydibenzoylmethane; etocrylene; and suitable sunscreens including 4-isopropyl-dibenzoylmethane.

[0129] In a preferred embodiment of the present invention, the ultraviolet light absorber or sunscreen is 2-ethylhexyl-p-methoxycinnamate, 4,4'-t-butylmethoxydibenzoyl-methane, 2-hydroxy-4-methoxybenzophenone, octyldimethyl-p-aminobenzoic acid, digalloyl trioleate, 2,2-dihydroxy-4-methoxybenzophenone, ethyl-4(bis(hydroxypropyl))aminobenzoate, 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, 2-ethyl The benzoxazole derivatives are selected from the group consisting of hexyl salicylate, glyceryl-p-aminobenzoate, 3,3,5-trimethylcyclohexyl salicylate, methyl anthranilate, p-dimethyl-aminobenzoic acid or aminobenzoate, 2-ethylhexyl-p-dimethyl-amino-benzoate, 2-phenylbenzimidazole-5-sulfonic acid, 2-(p-dimethylaminophenyl)-5-sulfonicbenzoxazoic acid, methylene bis-benzotriazolyl tetramethylbutylphenol, and mixtures thereof.

[0130] In one embodiment of the present invention, the thickener is selected from the group consisting of polymeric thickeners including non-ionic thickeners and anionic thickeners, or mixtures thereof. Suitable non-ionic thickeners include polyacrylamide polymers, cross-linked poly(N-vinylpyrrolidone), polysaccharides, natural or synthetic gums or polysaccharides, polyvinylpyrrolidone and polyvinyl alcohol. Suitable anionic thickeners include acrylic acid / ethyl acrylate copolymers, carboxyvinyl polymers, and cross-linked copolymers of alkyl vinyl ethers and maleic anhydride.

[0131] In one embodiment of the present invention, the thickening agent is selected from the group consisting of polysaccharides including cellulose, carboxymethyl hydroxyethyl cellulose, cellulose acetate propionate carboxylate, hydroxyethyl cellulose, hydroxyethyl ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl hydroxyethyl cellulose, microcrystalline cellulose, sodium cellulose sulfate and mixtures thereof, natural gums such as acacia, agar, alginic acid, ammonium alginate, amylopectin, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluronic acid, hydrated silicic acid, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboxymethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum and mixtures thereof.

[0132] In one embodiment of the present invention, the humectant is selected from the group consisting of sodium 2-pyrrolidone-5-carboxylate (NaPCA), guanidine, glycolic acid and its glycolate salts (e.g., ammonium and quaternary alkyl ammonium), lactic acid and its lactate salts (e.g., ammonium and quaternary alkyl ammonium), aloe vera in any of its various forms (e.g., aloe vera gel), hyaluronic acid and its derivatives (e.g., salt derivatives, e.g., sodium hyaluronate), lactamide monoethanolamine, acetamide monoethanolamine, urea, panthenol and its derivatives, and mixtures thereof.

[0133] In one embodiment of the present invention, the buffering agent is selected from the group consisting of lactic acid, lactate salts, gluconic acid, glucono-delta-lactone, sodium and potassium gluconate, trisodium citrate, tripotassium citrate, sodium and potassium lactate.

[0134] In one embodiment of the present invention, the solvent is selected from the group consisting of glycerin, diglycerin, triglycerin, polyglycerin, polypropylene glycol, polyethylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, hexylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, ethylene glycol monoalkyl ethers, diethylene glycol monoalkyl ethers, glucose, maltose, sucrose, lactose, xylitol, xylitol, sorbitol, mannitol, maltitol, malbit, panthenol, pentaerythritol, and polyhydric alcohols including hyaluronic acid and its salts, water, ethanol, and isopropanol.

[0135] In one embodiment of the present invention, the solvent is selected from the group consisting of glycerin, water and ethanol.

[0136] In one embodiment of the present invention, the preservative is selected from the group consisting of benzalkonium chloride, benzethonium chloride, benzyl alcohol, caprylyl glycol, chlorphenesin, 2,2'-dithiobis(N-methylbenzamide), diazolidinyl urea, ethylenediaminetetraacetic acid, ethylparaben, imidazolidinyl urea, methylparaben, phenoxyethanol, linoleamidopropyl PG-diammonium chloride phosphate, cocamidopropyl PG-diammonium chloride phosphate, propylparaben, cis-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride, dehydroacetic acid or a salt thereof, benzoic acid or a salt thereof, sodium hydroxymethylglycinate, and zinc pyrithione.

[0137] In one embodiment of the present invention, the liquid crystalline lipid particles are included in a topical composition further comprising a sunscreen, an ultraviolet light absorber, a thickener, and a solvent.

[0138] In a preferred embodiment of the present invention, the liquid crystalline lipid particles are included in a topical composition further comprising diethylamino hydroxybenzoyl hexyl benzoate, ethylhexyl methoxycinnamate, copolymer of acrylates / beheneth-25 methylacrylate, methylene bis-benzotriazolyl tetramethylbutylphenol, decyl glucoside, propylene glycol and xanthan gum, ethanol, water and butylene glycol.

[0139] The effect of the composition in providing barrier repair or maintaining the integrity of the outer layer of the skin can be applied to many different uses.For example, the composition can be used to treat any condition in which a defective or defective barrier is a factor.In this regard, the composition can be used to improve the long-term moisture retention of skin, or in the prevention or treatment of general dry skin conditions, or specific dry skin conditions resulting from, for example, habitual exposure to detergents, soaps and hot water; seasonal exposure to harsh weather conditions, such as cold, wind and / or sun; occupational exposure to harsh chemicals or other drying or damaging factors; or pathological conditions, such as eczematous dermatitis, psoriasis, ichthyosis, xerosis, etc.

[0140] Dry skin is also known to be commonly associated with aging (both natural and photoaging), and the present composition can be used to prevent further damage to aged skin, or to treat and / or repair existing damage, including the appearance of fine lines and wrinkles that are often associated with dry skin and the thinning of the stratum corneum that occurs with age. The present composition can also be used to treat defective skin barriers, such as those that occur on the soles and palms of the hands, where the stratum corneum is very thick but the lipid barrier is poor. In addition, defective skin barriers often occur in association with burns, trauma, blisters, stasis ulcers, and bed sores, and such injuries can be expected to benefit from the application of the present composition.

[0141] The composition of the present invention can be used to reduce the skin's response to irritants and sensitizers.A significant proportion of the population has sensitive skin, in that it frequently responds to various elements that skin may be exposed to through makeup or skin care products, environmental irritants such as smoking or pollution, or occupational exposure to chemicals, with stinging or painful reactions.In addition, even normal skin can react to exposure to known irritants, such as acid.

[0142] Since it is well known that the stratum corneum and lipids constitute the first line of defense against irritants by providing a physical barrier against the penetration of such substances into the lower skin layers, application of the compositions of the present invention can reduce the reactivity of the skin of both normal and sensitive individuals to irritants and sensitizers by increasing the integrity of the barrier; in one embodiment, for example, the compositions can be used to reduce the response of the skin to irritation caused by therapeutic acids, such as alpha- and beta-hydroxy acids, retinoic acid, etc., or to reduce irritation caused by insect bites or to alleviate the irritation experienced in contact dermatitis.

[0143] The composition of the present invention is applied in a manner suitable for the intended end use of the product.For example, in the treatment of occasional dry skin caused by exposure to weather or other temporary conditions, or in the treatment of occasional skin irritation, the composition can be used as needed until the condition is alleviated.When used to treat more permanent conditions, such as conditions related to defective or incomplete lipid barrier, particularly sensitive skin, dry skin related to any type of aging, or wrinkles or fine lines related to the thinning of the stratum corneum with age, the composition is preferably applied chronically to prevent the condition from recurring.

[0144] In one embodiment, the composition of the present invention has a concentration of about 0.1 mg / cm 2 of skin ~2mg / 1cm 2of skin from about once per week to about four or five times per day, preferably from about three times per week to about three times per day, and most preferably about once or twice per day.

[0145] Additionally, the compositions of the present invention may be applied for longer durations, preferably for periods of at least about one month, from about three months to about twenty years, more preferably from about six months to about ten years, and even more preferably from about one year to about five years, thereby resulting in the treatment or prevention of the targeted condition.

[0146] advantage: 1. Liquid crystalline lipid particles have a defined shape, thereby mimicking the skin structure. 2. The liquid crystalline lipid particles contained in the composition form a flexible film on the skin, so that the skin can be protected from pollutants and provide moisturizing effect to the skin. 3. The liquid crystalline lipid particle composition is stable under various temperature conditions.

[0147] Embodiment 1. A method for reducing dust adhesion to skin comprising applying at least one liquid crystalline lipid particle to the skin, The liquid crystalline lipid particles are At least one compound of formula (I)

[0148] [ka] [In the formula, m is an integer ranging from 10 to 24, and n is an integer ranging from 1 to 25] At least one compound of formula (II)

[0149] [ka] [wherein a is an integer ranging from 10 to 24], At least one compound of formula (III)

[0150] [ka] [wherein x is an integer ranging from 10 to 24, and y is an integer ranging from 10 to 25], At least one compound of formula (IV)

[0151] [ka] [wherein p is an integer ranging from 10 to 16], At least one compound of formula (V)

[0152] [ka] [In the formula, A and B each independently represent a hydrogen atom or an alkaline earth metal; R is a linear or branched, saturated or unsaturated C 10 ~C 20 an aliphatic group], and At least one compound of formula (VI)

[0153] [ka] [In the formula, r is an integer ranging from 9 to 18, and M is a hydrogen atom, an alkaline earth metal, or an alkaline earth metal.] The method comprises the step of preparing a compound represented by any one of the general formulas (I) to (VI): 2. Use of at least one liquid crystalline lipid particle for reducing dust adhesion to the skin, the liquid crystalline lipid particle comprising: At least one compound of formula (I)

[0154] [ka] [In the formula, m is an integer ranging from 10 to 24, and n is an integer ranging from 1 to 25] At least one compound of formula (II)

[0155] [ka] [wherein a is an integer ranging from 10 to 24], At least one compound of formula (III)

[0156] [ka] [wherein x is an integer ranging from 10 to 24, and y is an integer ranging from 10 to 25], At least one compound of formula (IV)

[0157] [ka] [wherein p is an integer ranging from 10 to 16], At least one compound of formula (V)

[0158] [ka] [In the formula, A and B each independently represent a hydrogen atom or an alkaline earth metal; R is a linear or branched, saturated or unsaturated C 10 ~C 20 an aliphatic group], and At least one compound of formula (VI)

[0159] [ka] [In the formula, r is an integer ranging from 9 to 18, and M is a hydrogen atom, an alkaline earth metal, or an alkaline earth metal.] The use of the compound represented by the general formulas (I) to (VI). 3. The method or use according to embodiment 1 or 2, wherein the liquid crystalline lipid particles have a lamellar structure with orthorhombic lateral packing. 4. The method or use according to embodiment 1 or 2, wherein the liquid crystalline lipid particles have an average particle size in the range of 20 nm to 300 nm, as determined using dynamic light scattering using a Malvern DLS ZS90. 5. The method or use according to embodiment 1 or 2, wherein the liquid crystalline lipid particles have a zeta potential of more than 20 mV. 6. The method or use according to any one of the preceding embodiments, wherein the at least one compound of general formula (I) is selected from the group consisting of ceteareth, polyoxyethylene stearyl ether and polyoxyethylene cetyl ether. 7. The method or use according to any one of the preceding embodiments, wherein the at least one compound of general formula (II) is selected from the group consisting of glyceryl stearate, glyceryl laurate and glyceryl palmitate. 8. The method or use according to any one of the preceding embodiments, wherein the at least one compound of general formula (III) is selected from the group consisting of cetyl palmitate, myristyl myristate, tetradecyl tetradecanoate and behenyl behenate. 9. The method or use according to any one of the preceding embodiments, wherein the at least one compound of general formula (IV) is selected from the group consisting of lauryl alcohol, tridecyl alcohol, myristyl alcohol, pentadecyl alcohol, cetyl alcohol, palmitoleic alcohol, heptadecyl alcohol, stearyl alcohol or mixtures thereof. 10. At least one compound of general formula (V) is disodium C 10 ~C 18 10. The method or use according to embodiment 1 to 9, wherein the alkyl sulfosuccinate is an alkyl sulfosuccinate. 11. The method or use according to any one of the preceding embodiments, wherein the at least one compound of general formula (VI) is selected from the group consisting of sodium lauroyl glutamate, sodium cocoyl glutamate, sodium myristoyl glutamate and sodium stearoyl glutamate. 12. The method or use according to any one of the preceding embodiments, wherein the liquid crystalline lipid particles comprise ceteareth, glyceryl stearate, cetyl palmitate, cetyl alcohol and stearyl alcohol. 13. The use according to any one of the preceding embodiments, wherein the liquid crystalline lipid particles comprise ceteareth, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol and stearyl alcohol. 14. The liquid crystal lipid particles are made of ceteareth, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol, and disodium C 10 ~C 18 The use according to any one of the preceding embodiments, comprising a compound selected from the group of alkyl sulfosuccinates and sodium stearoyl glutamate. 15. The liquid crystalline lipid particles are made of ceteareth-12, ceteareth-12, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol, and disodium C 16 ~C 18 The use according to any one of the preceding embodiments, comprising a compound selected from the group of alkyl sulfosuccinates and sodium stearoyl glutamate. 16. At least one type of liquid crystal particle according to any one of embodiments 1 to 15; At least one thickener; and water. 17. The topical composition of embodiment 16, wherein the at least one thickening agent is selected from the group consisting of xanthan gum, succinoglycan, gellan gum, pectin, alginate, starch, guar, acrylate, acrylate copolymer, carbomer, and associative thickeners. 18. The topical composition of embodiment 16 or 17, wherein the at least one liquid crystalline lipid particle is present in an amount ranging from 1% to 30% by weight based on the total weight of the topical composition. 19. A topical composition according to any one of embodiments 16 to 18, wherein at least one thickener is present in an amount ranging from 0.1% by weight to 5% by weight, based on the total weight of the topical composition. 20. A topical composition according to any one of embodiments 16 to 19, wherein water is present in an amount ranging from 5% by weight to 80% by weight, based on the total weight of the topical composition. 21. The topical composition of any one of embodiments 16 to 20, further comprising at least one adjuvant selected from the group consisting of anti-wrinkle actives, anti-acne actives, emulsifiers, antioxidants, emollients, self-tanning actives, whitening agents, sunscreens, humectants, abrasives, absorbents, fragrances, buffers, opacifiers, colorants, preservatives, fillers, and pH adjusters. 22. The topical composition according to any one of embodiments 16 to 21, which is a skin care composition. 23. The topical composition according to any one of embodiments 12 to 22, which is in the form of a cream, foam, lotion, gel, paste or ointment. 24. A method for reducing dust adhesion to skin, comprising applying to the skin a topical composition described in any one of embodiments 16 to 23. EXAMPLES

[0160] Examples are now set forth below to illustrate methods and results based on the presently disclosed subject matter. These examples are not intended to be inclusive of all aspects of the subject matter disclosed herein, but rather to illustrate representative methods, compositions, and results. These examples are not intended to exclude equivalents and modifications of the present invention that are obvious to those skilled in the art.

[0161] material: Materials from BASF: Emulgade® SE-PF is a mixture of glyceryl stearate, ceteareth-20, ceteareth-12, cetyl alcohol, and cetyl palmitate, which are emulsifying bases. Eumulgin® B1 is ceteareth-12 (cetylstearyl alcohol with 12 mol EO), a non-ionic emulsifier. · Cetiol® MM is myristyl myristate, an emollient. Eumulgin® Prisma is a disodium C16-C18 alkyl sulfosuccinate, an anionic emulsifier. · Eumulgin® SG is sodium stearoyl glutamate, an anionic emulsifier. · Uvinul® A Plus is diethylaminohydroxybenzoyl hexyl benzoate, an ultraviolet light absorber. · Uvinul® MC 80 is ethylhexyl methoxycinnamate, an ultraviolet light absorber. · Tinovis® GTC is an acrylates / beheneth-25 methylacrylate copolymer and is a thickener or viscosity modifier. Rhenocare® XGN is a xanthan gum, a thickener or viscosity modifier. · Tinisorb® M is methylene bis-benzotriazolyl tetramethylbutylphenol, water, decyl glucoside, propylene glycol and xanthan gum, an ultraviolet light filter. From Clariant Phenonip® is phenoxyethanol (and) methylparaben (and) ethylparaben (and) propylparaben (and) butylparaben (and) isobutylparaben, used as a broad spectrum antimicrobial agent and preservative.

[0162] method: Particle size measurements: Particle size measurements of the liquid crystalline lipid particles were performed using a Malvern DLS ZS90. Zeta potential measurement: Zeta potential was measured using a Zetasizer nano ZS90 (Malvern).

[0163] [Example 1] Base composition of liquid crystalline lipid particles

[0164] [Table 1]

[0165] Manufacturing process: phase inversion temperature emulsification method 1) Part A and Part B ingredients were heated separately to 80°C. 2) Part A was added to Part B and mixed using a homogenizer until uniform to form the base. 3) Part C was mixed into the base from step 2. 4) The base formed in step 4 was cooled to room temperature in an ice bath. 5) Part D was added to the base and mixed using a homogenizer until uniform.

[0166] result

[0167] [Table 2]

[0168] [Example 2]

[0169] [Table 3]

[0170] Manufacturing Process: 1) Part A and Part B ingredients were heated separately to 80°C. 2) Part A was added to Part B with homogenization and mixed until homogenous. 3) Part C was mixed with the mixture of Parts A and B and cooled to 45°C. 4) Part D was added to the mixture of step 3 and mixed using a homogenizer until homogenous. It was then cooled to room temperature.

[0171] [Example 3] Anti-dust Performance - Test Protocol 1) 4 g of each of the compositions according to Examples 2T1 to 2T3 was applied onto a PMMA board. 2) 2g of composition was further applied to the board to ensure even distribution of the composition on the board. 3) The board was placed in a 38° C. oven overnight. 4) The board was placed upside down on the plate on which the dust was weighed and gently shaken for 30 seconds. 5) The board was turned upside down again and the plate was weighed relative to the sand.

[0172] result

[0173] [Table 4] The lower dusting in Example 3T2 indicates the superior performance of the composition containing liquid crystalline lipid particles as a base.

[0174] Referring to Figures 3 and 4, a reduction in dust adhesion to the skin surface following application of a composition containing liquid crystalline lipid particles is shown.

[0175] [Example 4] Testing moisturizing effect

[0176] [Table 5]

[0177] Manufacturing Process 1) Dissolve Part A at 80°C. 2) Cool the base to room temperature and then add Part B to the base. Mix until homogenous.

[0178] Results: The composition of Example 4T5 demonstrated a 3-fold increase in moisturizing effect compared to Example 4T4, as measured by a Corneometer. Figure 5 shows the results of Example 4T4.

Claims

1. 1. A method for reducing dust adhesion to skin, comprising applying at least one liquid crystalline lipid particle to the skin, The liquid crystalline lipid particles are At least one compound of formula (I) 【Chemistry 1】 [wherein m is an integer ranging from 10 to 24, and n is an integer ranging from 1 to 25], At least one compound of formula (II) 【Chemistry 2】 [wherein a is an integer ranging from 10 to 24], At least one compound of formula (III) 【Chemistry 3】 [wherein x is an integer ranging from 10 to 24, and y is an integer ranging from 10 to 25], At least one compound of formula (IV) 【Chemistry 4】 [wherein p is an integer ranging from 10 to 16], At least one compound of formula (V) 【Chemistry 5】 [In the formula, A and B each independently represent a hydrogen atom or an alkaline earth metal; R is a linear or branched, saturated or unsaturated C 10 ~C 20 an aliphatic group], and At least one compound of formula (VI) 【Chemistry 6】 [In the formula, r is an integer ranging from 9 to 18, and M is a hydrogen atom, an alkaline earth metal, or an alkaline earth metal.] The method of claim 1, comprising administering to a subject a compound represented by general formula (I)-(VI):

2. 1. Use of at least one liquid crystalline lipid particle for reducing dust adhesion to skin, comprising: At least one compound of formula (I) 【Chemistry 7】 [wherein m is an integer ranging from 10 to 24, and n is an integer ranging from 1 to 25], At least one compound of formula (II) 【Chemistry 8】 [wherein a is an integer ranging from 10 to 24], At least one compound of formula (III) 【Chemistry 9】 [wherein x is an integer ranging from 10 to 24, and y is an integer ranging from 10 to 25], At least one compound of formula (IV) 【Chemistry 10】 [wherein p is an integer ranging from 10 to 16], At least one compound of formula (V) 【Chemistry 11】 [In the formula, A and B each independently represent a hydrogen atom or an alkaline earth metal; R is a linear or branched, saturated or unsaturated C 10 ~C 20 an aliphatic group], and At least one compound of formula (VI) 【Chemistry 12】 [In the formula, r is an integer ranging from 9 to 18, and M is a hydrogen atom, an alkaline earth metal, or an alkaline earth metal.] The use of the compound represented by the general formula (I) to (VI)

3. 3. The method or use according to claim 1 or 2, wherein the liquid crystalline lipid particles have a lamellar structure with orthorhombic lateral packing.

4. 3. The method or use according to claim 1 or 2, wherein the liquid crystalline lipid particles have an average particle size in the range of 20 nm to 300 nm, as determined using dynamic light scattering using a Malvern DLS ZS90.

5. 3. The method or use according to claim 1 or 2, wherein the liquid crystalline lipid particles have a zeta potential of more than 20 mV.

6. 6. The method or use according to any one of claims 1 to 5, wherein the at least one compound of general formula (I) is selected from the group consisting of ceteareth, polyoxyethylene stearyl ether and polyoxyethylene cetyl ether.

7. 7. The method or use according to any one of claims 1 to 6, wherein the at least one compound of general formula (II) is selected from the group consisting of glycerol stearate, glycerol laurate and glycerol palmitate.

8. 8. The method or use according to any one of claims 1 to 7, wherein the at least one compound of general formula (III) is selected from the group consisting of cetyl palmitate, myristyl myristate, tetradecyl tetradecanoate and behenyl behenate.

9. 9. The method or use according to any one of claims 1 to 8, wherein the at least one compound of general formula (IV) is selected from the group consisting of lauryl alcohol, tridecyl alcohol, myristyl alcohol, pentadecyl alcohol, cetyl alcohol, palmitoleic alcohol, heptadecyl alcohol, stearyl alcohol or mixtures thereof.

10. At least one compound of general formula (V) is 10 ~C 18 10. The method or use according to any one of claims 1 to 9, which is an alkyl sulfosuccinate.

11. 11. The method or use according to any one of claims 1 to 10, wherein the at least one compound of general formula (VI) is selected from the group consisting of sodium lauroyl glutamate, sodium cocoyl glutamate, sodium myristoyl glutamate and sodium stearoyl glutamate.

12. 12. The method or use according to any one of claims 1 to 11, wherein the liquid crystalline lipid particles comprise ceteareth, glyceryl stearate, cetyl palmitate, cetyl alcohol and stearyl alcohol.

13. 12. The use according to any one of claims 1 to 11, wherein the liquid crystalline lipid particles comprise ceteareth, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol and stearyl alcohol.

14. The liquid crystal lipid particles are made of ceteareth, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol, and disodium C 10 ~C 18 12. Use according to any one of claims 1 to 11, comprising a compound selected from the group of alkyl sulfosuccinates and sodium stearoyl glutamate.

15. The liquid crystalline lipid particles are made of ceteareth-12, ceteareth-12, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol, and disodium C 16 ~C 18 12. Use according to any one of claims 1 to 11, comprising a compound selected from the group of alkyl sulfosuccinates and sodium stearoyl glutamate.

16. At least one liquid crystal particle according to any one of claims 1 to 15; At least one thickener; and water.

17. 17. The topical composition of claim 16, wherein the at least one thickening agent is selected from the group consisting of xanthan gum, succinoglycan, gellan gum, pectin, alginate, starch, guar, acrylates, acrylate copolymers, carbomers, and associative thickeners.

18. 18. The topical composition according to claim 16 or 17, wherein the at least one type of liquid crystalline lipid particles is present in an amount ranging from 1% to 30% by weight, based on the total weight of the topical composition.

19. The topical composition of any one of embodiments 16 to 18, wherein the at least one thickening agent is present in an amount ranging from 0.1 wt.% to 5 wt.% based on the total weight of the topical composition.

20. 20. The topical composition of claim 16, wherein water is present in an amount ranging from 5% to 80% by weight, based on the total weight of the topical composition.

21. 21. The topical composition of any one of claims 16 to 20, further comprising at least one adjuvant selected from the group consisting of anti-wrinkle actives, anti-acne actives, emulsifiers, antioxidants, emollients, self-tanning actives, whitening agents, sunscreens, humectants, abrasives, absorbents, fragrances, buffers, opacifiers, colorants, preservatives, fillers, and pH adjusters.

22. 22. The topical composition of any one of claims 16 to 21, which is a skin care composition.

23. 23. The topical composition according to any one of claims 12 to 22, which is in the form of a cream, foam, lotion, gel, paste or ointment.

24. 24. A method for reducing dust adhesion to skin comprising applying to the skin a topical composition according to any one of claims 16 to 23.

Images